• About us
• Contact

Advertisement

Organisation › Details

Owlstone Ltd.

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020. The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved. Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications. Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge University, Owlstone Inc is a profitable business selling its proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications. Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK. *

 

	Start	2014-07-05 reorganised before
	Group	Owlstone (Group)
	Industry	FAIMS technology
	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	127 Milton Road Cambridge Science Park
	City	CB4 0GD Cambridge, Cambridgeshire
	Tel	+44-1223-428200
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for Owlstone (Group)

• [1] Owlstone Medical Ltd.. (1/15/25). "Press Release: Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round". Cambridge....
• [2] Owlstone Medical Ltd.. (4/25/24). "Press Release: Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease". Cambridge....
• [3] Owlstone Medical Ltd.. (3/15/23). "Press Release: Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection". Cambridge....
• [4] Owlstone Medical Ltd.. (9/7/21). "Press Release: Owlstone Medical Closes $58 Million USD (c. £42 Million GBP) Oversubscribed Financing Round to Continue to Advance Breath Biopsy". Cambridge....
• [5] Owlstone Medical Ltd.. (3/30/20). "Press Release: Owlstone Medical Appoints Neil Tween as Chief Financial Officer". Cambridge....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2026. Made in Germany.